

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Cancelled).
2. (Cancelled).
3. (Currently amended) An anti-cancer ~~vaccine~~ composition comprising an antigen, ~~in association with an effective amount of at least one immunomodulator chemotherapeutic compound~~ adjuvant eliciting an immune response in a patient and a pharmaceutically acceptable carrier, said composition eliciting an immune response in a patient and wherein said antigen is inactivated tumor cells from a cancer targeted by said anti-cancer composition.
4. (Currently amended) The anti-cancer ~~composition~~ vaccine of claim 3, wherein said antigen is tumor cells inactivated by said chemotherapeutic ~~agent~~ compound.
5. (Currently amended) The anti-cancer ~~composition~~ vaccine of claim 3, wherein said tumor cells are inactivated by radiotherapy and/or chemotherapy.
6. (Currently amended) The anti-cancer ~~composition~~ vaccine of claim 3, wherein said tumor cells are inactivated by radiotherapy.
7. (Currently amended) The anti-cancer ~~composition~~ vaccine of any one of claims 3-6, wherein said ~~composition~~ vaccine is eliciting an immunoprotective response against a cancer selected from the group consisting of basal cell carcinoma, bladder cancer, bone cancer, brain cancer, CNS cancer, breast cancer, cervical cancer, colon cancer, rectum cancer, connective tissue cancer, esophageal cancer, eye cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, melanoma, myeloma, leukemia, oral cavity cancer, ovarian cancer, pancreatic cancer, prostate cancer, rhabdomyosarcoma, skin cancer, stomach cancer, testicular cancer, neoplasia and uterine cancer.
8. (Currently amended) The anti-cancer ~~composition~~ vaccine of any one of claims 3-6, wherein said ~~composition~~ vaccine is eliciting an immune response against a cancer selected from

the group consisting of bladder cancer, prostate cancer, melanoma, breast cancer, colon cancer, lung cancer, liver cancer, lymphoma, myeloma, leukemia and ovarian cancer.

9. (Currently amended) The anti-cancer composition~~vaccine~~ of claim 3, wherein said chemotherapeutic ~~adjuvant~~compound is a taxane.

10. (Currently amended) The anti-cancer composition~~vaccine~~ of claim 3, wherein said chemotherapeutic compound~~adjuvant~~ is selected from the group consisting of Cyclophosphamide, Doxorubicin, Cisplatin, Paclitaxel and 5-fluorouracil.

11. (Currently amended) The anti-cancer composition~~vaccine~~ of any one of claim 3-10, further comprising a therapeutically effective amount of a therapeutic agent.

12. (Currently amended) The anti-cancer ~~vaccine~~composition—of claim 11, wherein said therapeutic agent is selected from the group consisting of cytokine, antibody, systemic chemotherapeutic agent, biological response modifier and hormones.

13. (Cancelled).

14. (Currently amended) The anti-cancer composition~~vaccine~~ of claim 12, wherein said biological response modifier is selected from the group consisting of interferon and lymphokine.

15. (Currently amended) The anti-cancer composition~~vaccine~~ of claim 14, wherein said lymphokine is IL-2.

16. (Currently amended) The anti-cancer composition~~vaccine~~ of any one of claims 3-12 and 14-15, further comprising a non-chemotherapeutic adjuvant selected from the group consisting of polysaccharides, CpG nucleic acids, MF59, SAF, MPL and QS21.

17. (Currently amended) The anti-cancer composition~~vaccine~~ of any one of claims 3-12 and 14-16, further comprising a non-chemotherapeutic compound~~adjuvant~~ selected from the group consisting of adjuvantcompounds that create a local reservoir of drug, adjuvants—compounds that stimulate the immune system, mucosal compounds~~adjuvants~~, phosphazene and *Leishmania* elongation factor.

18-38. (Cancelled).